Effect of myeloperoxidase oxidation and
N-homocyteinylation
acute myocardial infarction (AMI)
high-density lipoprotein (HDL)
myeloperoxidase (MPO)
wound repair
Journal
Biological chemistry
ISSN: 1437-4315
Titre abrégé: Biol Chem
Pays: Germany
ID NLM: 9700112
Informations de publication
Date de publication:
23 02 2022
23 02 2022
Historique:
received:
01
05
2021
accepted:
09
08
2021
pubmed:
28
8
2021
medline:
3
5
2022
entrez:
27
8
2021
Statut:
epublish
Résumé
Endothelial cell (EC) migration is essential for healing vascular injuries. Previous studies suggest that high-density lipoprotein (HDL) and apolipoprotein A-I (apoA-I), the major protein constituent of HDL, have endothelial healing functions. In cardiovascular disease, HDL is modified by myeloperoxidase (MPO) and
Identifiants
pubmed: 34448387
pii: hsz-2021-0247
doi: 10.1515/hsz-2021-0247
doi:
Substances chimiques
Apolipoprotein A-I
0
Apolipoprotein A-II
0
Lipoproteins, HDL
0
Peroxidase
EC 1.11.1.7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
265-277Informations de copyright
© 2022 Takahiro Kameda et al., published by De Gruyter, Berlin/Boston.
Références
Al-Obaidi, M.K., Stubbs, P.J., Collinson, P., Conroy, R., Graham, I., and Noble, M.I. (2000). Elevated homocysteine levels are associated with increased ischemic myocardial injury in acute coronary syndromes. J. Am. Coll. Cardiol. 36: 1217–1222, https://doi.org/10.1016/s0735-1097(00)00820-2.
Alam, N., Khan, H.I., Chowdhury, A.W., Haque, M.S., Ali, M.S., Sabah, K.M., and Amin, M.G. (2012). Elevated serum homocysteine level has a positive correlation with serum cardiac troponin I in patients with acute myocardial infarction. Bangladesh Med. Res. Counc. Bull. 38: 9–13, https://doi.org/10.3329/bmrcb.v38i1.10445.
Albelda, S.M., Smith, C.W., and Ward, P.A. (1994). Adhesion molecules and inflammatory injury. Faseb. J. 8: 504–512, https://doi.org/10.1096/fasebj.8.8.8181668.
Barter, P.J., Nicholls, S., Rye, K.A., Anantharamaiah, G.M., Navab, M., and Fogelman, A.M. (2004). Antiinflammatory properties of HDL. Circ. Res. 95: 764–772, https://doi.org/10.1161/01.res.0000146094.59640.13.
Boden, W.E. (2000). High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from framingham to the veterans affairs high-density lipoprotein intervention trial. Am. J. Cardiol. 86: 19l–22l, https://doi.org/10.1016/s0002-9149(00)01464-8.
Borup, A., Christensen, P.M., Nielsen, L.B., and Christoffersen, C. (2015). Apolipoprotein M in lipid metabolism and cardiometabolic diseases. Curr. Opin. Lipidol. 26: 48–55, https://doi.org/10.1097/mol.0000000000000142.
Brown, B.E., Nobecourt, E., Zeng, J., Jenkins, A.J., Rye, K.A., and Davies, M.J. (2013). Apolipoprotein A-I glycation by glucose and reactive aldehydes alters phospholipid affinity but not cholesterol export from lipid-laden macrophages. PloS One 8: e65430, https://doi.org/10.1371/journal.pone.0065430.
Cabana, V.G., Feng, N., Reardon, C.A., Lukens, J., Webb, N.R., de Beer, F.C., and Getz, G.S. (2004). Influence of apoA-I and apoE on the formation of serum amyloid A-containing lipoproteins in vivo and in vitro. J. Lipid Res. 45: 317–325, https://doi.org/10.1194/jlr.m300414-jlr200.
Cattaneo, M. (2001). Hyperhomocysteinemia and thrombosis. Lipids 36: S13–S26, https://doi.org/10.1007/s11745-001-0677-9.
Christoffersen, C., Obinata, H., Kumaraswamy, S.B., Galvani, S., Ahnström, J., Sevvana, M., Egerer-Sieber, C., Muller, Y.A., Hla, T., Nielsen, L.B., et al.. (2011). Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc. Natl. Acad. Sci. U.S.A. 108: 9613–9618, https://doi.org/10.1073/pnas.1103187108.
Cockerill, G.W., Rye, K.A., Gamble, J.R., Vadas, M.A., and Barter, P.J. (1995). High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 15: 1987–1994, https://doi.org/10.1161/01.atv.15.11.1987.
Coetzee, G.A., Strachan, A.F., van der Westhuyzen, D.R., Hoppe, H.C., Jeenah, M.S., and de Beer, F.C. (1986). Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J. Biol. Chem. 261: 9644–9651, https://doi.org/10.1016/s0021-9258(18)67562-3.
de Souza, J.A., Vindis, C., Negre-Salvayre, A., Rye, K.A., Couturier, M., Therond, P., Chantepie, S., Salvayre, R., Chapman, M.J., and Kontush, A. (2010). Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I. J. Cell Mol. Med. 14: 608–620, https://doi.org/10.1111/j.1582-4934.2009.00713.x.
Feng, P.N., Liang, Y.R., Lin, W.B., Yao, Z.R., Chen, D.B., Chen, P.S., and Ouyang, J. (2018). Homocysteine induced oxidative stress in human umbilical vein endothelial cells via regulating methylation of SORBS1. Eur. Rev. Med. Pharmacol. Sci. 22: 6948–6958, https://doi.org/10.26355/eurrev_201810_16164.
Garner, B., Waldeck, A.R., Witting, P.K., Rye, K.A., and Stocker, R. (1998). Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J. Biol. Chem. 273: 6088–6095, https://doi.org/10.1074/jbc.273.11.6088.
Gong, M., Wilson, M., Kelly, T., Su, W., Dressman, J., Kincer, J., Matveev, S.V., Guo, L., Guerin, T., Li, X.A., et al.. (2003). HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner. J. Clin. Invest. 111: 1579–1587, https://doi.org/10.1172/jci16777.
Handy, D.E., Zhang, Y., and Loscalzo, J. (2005). Homocysteine down-regulates cellular glutathione peroxidase (GPx1) by decreasing translation. J. Biol. Chem. 280: 15518–15525, https://doi.org/10.1074/jbc.m501452200.
Havel, R.J., Eder, H.A., and Bragdon, J.H. (1955). The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34: 1345–1353, https://doi.org/10.1172/jci103182.
Hoang, A., Murphy, A.J., Coughlan, M.T., Thomas, M.C., Forbes, J.M., O’Brien, R., Cooper, M.E., Chin-Dusting, J.P., and Sviridov, D. (2007). Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia 50: 1770–1779, https://doi.org/10.1007/s00125-007-0718-9.
Hu, H., Wang, C., Jin, Y., Meng, Q., Liu, Q., Liu, Z., Liu, K., Liu, X., and Sun, H. (2019). Catalpol inhibits homocysteine-induced oxidation and inflammation via inhibiting Nox4/NF-κB and GRP78/PERK pathways in human aorta endothelial cells. Inflammation 42: 64–80, https://doi.org/10.1007/s10753-018-0873-9.
Hwang, S.J., Ballantyne, C.M., Sharrett, A.R., Smith, L.C., Davis, C.E., Gotto, A.M.Jr., and Boerwinkle, E. (1997). Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 96: 4219–4225, https://doi.org/10.1161/01.cir.96.12.4219.
Ishimine, N., Usami, Y., Nogi, S., Sumida, T., Kurihara, Y., Matsuda, K., Nakamura, K., Yamauchi, K., Okumura, N., and Tozuka, M. (2010). Identification of N-homocysteinylated apolipoprotein AI in normal human serum. Ann. Clin. Biochem. 47: 453–459, https://doi.org/10.1258/acb.2010.010035.
Jakubowski, H. (1997). Metabolism of homocysteine thiolactone in human cell cultures. Possible mechanism for pathological consequences of elevated homocysteine levels. J. Biol. Chem. 272: 1935–1942, https://doi.org/10.1016/s0021-9258(19)67504-6.
Jakubowski, H. (1999). Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. Faseb. J. 13: 2277–2283, https://doi.org/10.1096/fasebj.13.15.2277.
Jakubowski, H. (2002). Homocysteine is a protein amino acid in humans. Implications for homocysteine-linked disease. J. Biol. Chem. 277: 30425–30428, https://doi.org/10.1074/jbc.c200267200.
Jayaraman, S., Gantz, D.L., and Gursky, O. (2008). Effects of protein oxidation on the structure and stability of model discoidal high-density lipoproteins. Biochemistry 47: 3875–3882, https://doi.org/10.1021/bi7023783.
Kameda, T., Ohkawa, R., Yano, K., Usami, Y., Miyazaki, A., Matsuda, K., Kawasaki, K., Sugano, M., Kubota, T., and Tozuka, M. (2015). Effects of myeloperoxidase-induced oxidation on antiatherogenic functions of high-density lipoprotein. J. Lipids 2015: 592594, https://doi.org/10.1155/2015/592594.
Kameda, T., Usami, Y., Shimada, S., Haraguchi, G., Matsuda, K., Sugano, M., Kurihara, Y., Isobe, M., and Tozuka, M. (2012). Determination of myeloperoxidase-induced apoAI-apoAII heterodimers in high-density lipoprotein. Ann. Clin. Lab. Sci. 42: 384–391.
Lentz, S.R. (2001). Does homocysteine promote atherosclerosis? Arterioscler. Thromb. Vasc. Biol. 21: 1385–1386, https://doi.org/10.1161/atvb.21.9.1385.
Liao, D., Tan, H., Hui, R., Li, Z., Jiang, X., Gaubatz, J., Yang, F., Durante, W., Chan, L., Schafer, A.I., et al.. (2006). Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I protein synthesis and enhancing HDL cholesterol clearance. Circ. Res. 99: 598–606, https://doi.org/10.1161/01.res.0000242559.42077.22.
Liu, W., Wang, T., Sun, P., and Zhou, Y. (2019). Expression of Hcy and blood lipid levels in serum of CHD patients and analysis of risk factors for CHD. Exp. Ther. Med. 17: 1756–1760, https://doi.org/10.3892/etm.2018.7111.
Lu, N., Xie, S., Li, J., Tian, R., and Peng, Y.Y. (2015). Myeloperoxidase-mediated oxidation targets serum apolipoprotein A-I in diabetic patients and represents a potential mechanism leading to impaired anti-apoptotic activity of high density lipoprotein. Clin. Chim. Acta 441: 163–170, https://doi.org/10.1016/j.cca.2014.12.014.
Lv, P., Tong, X., Peng, Q., Liu, Y., Jin, H., Liu, R., Sun, W., Pan, B., Zheng, L., and Huang, Y. (2016). Treatment with the herbal medicine, naoxintong improves the protective effect of high-density lipoproteins on endothelial function in patients with type 2 diabetes. Mol. Med. Rep. 13: 2007–2016, https://doi.org/10.3892/mmr.2016.4792.
Malle, E., Marsche, G., Arnhold, J., and Davies, M.J. (2006). Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochim. Biophys. Acta 1761: 392–415, https://doi.org/10.1016/j.bbalip.2006.03.024.
Mikael, L.G., Genest, J.Jr., and Rozen, R. (2006). Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ. Res. 98: 564–571, https://doi.org/10.1161/01.res.0000204825.66410.0b.
Miyazaki, A., Sagae, N., Usami, Y., Sato, M., Kameda, T., Yoshimoto, A., Ishimine, N., Matsuda, K., Sugano, M., Hara, M., et al.. (2014). N-homocysteinylation of apolipoprotein A-I impairs the protein’s antioxidant ability but not its cholesterol efflux capacity. Biol. Chem. 395: 641–648, https://doi.org/10.1515/hsz-2013-0262.
Moselhy, S.S. and Demerdash, S.H. (2003). Plasma homocysteine and oxidative stress in cardiovascular disease. Dis. Markers 19: 27–31, https://doi.org/10.1155/2003/137047.
Navab, M., Hama, S.Y., Cooke, C.J., Anantharamaiah, G.M., Chaddha, M., Jin, L., Subbanagounder, G., Faull, K.F., Reddy, S.T., Miller, N.E., et al.. (2000a). Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J. Lipid Res. 41: 1481–1494, https://doi.org/10.1016/s0022-2275(20)33461-1.
Navab, M., Hama, S.Y., Anantharamaiah, G.M., Hassan, K., Hough, G.P., Watson, A.D., Reddy, S.T., Sevanian, A., Fonarow, G.C., and Fogelman, A.M. (2000b). Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J. Lipid Res. 41: 1495–1508, https://doi.org/10.1016/s0022-2275(20)33462-3.
Nussbaum, C., Klinke, A., Adam, M., Baldus, S., and Sperandio, M. (2013). Myeloperoxidase: a leukocyte-derived protagonist of inflammation and cardiovascular disease. Antioxidants Redox Signal. 18: 692–713, https://doi.org/10.1089/ars.2012.4783.
Oemar, B.S., Tschudi, M.R., Godoy, N., Brovkovich, V., Malinski, T., and Lüscher, T.F. (1998). Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation 97: 2494–2498, https://doi.org/10.1161/01.cir.97.25.2494.
Pan, B., Yu, B., Ren, H., Willard, B., Pan, L., Zu, L., Shen, X., Ma, Y., Li, X., Niu, C., et al.. (2013). High-density lipoprotein nitration and chlorination catalyzed by myeloperoxidase impair its effect of promoting endothelial repair. Free Radic. Biol. Med. 60: 272–281, https://doi.org/10.1016/j.freeradbiomed.2013.02.004.
Pankhurst, G., Wang, X.L., Wilcken, D.E., Baernthaler, G., Panzenbock, U., Raftery, M., and Stocker, R. (2003). Characterization of specifically oxidized apolipoproteins in mildly oxidized high density lipoprotein. J. Lipid Res. 44: 349–355, https://doi.org/10.1194/jlr.m200256-jlr200.
Podrez, E.A., Abu-Soud, H.M., and Hazen, S.L. (2000). Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic. Biol. Med. 28: 1717–1725, https://doi.org/10.1016/s0891-5849(00)00229-x.
Refsum, H., Ueland, P.M., Nygard, O., and Vollset, S.E. (1998). Homocysteine and cardiovascular disease. Annu. Rev. Med. 49: 31–62, https://doi.org/10.1146/annurev.med.49.1.31.
Rubin, E.M., Krauss, R.M., Spangler, E.A., Verstuyft, J.G., and Clift, S.M. (1991). Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353: 265–267, https://doi.org/10.1038/353265a0.
Sato, M., Ohkawa, R., Yoshimoto, A., Yano, K., Ichimura, N., Nishimori, M., Okubo, S., Yatomi, Y., and Tozuka, M. (2016). Effects of serum amyloid A on the structure and antioxidant ability of high-density lipoprotein. Biosci. Rep. 36: e00369, https://doi.org/10.1042/BSR20160075.
Shao, B., Bergt, C., Fu, X., Green, P., Voss, J.C., Oda, M.N., Oram, J.F., and Heinecke, J.W. (2005). Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport. J. Biol. Chem. 280: 5983–5993, https://doi.org/10.1074/jbc.m411484200.
Shao, B., Pennathur, S., Pagani, I., Oda, M.N., Witztum, J.L., Oram, J.F., and Heinecke, J.W. (2010a). Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the ABCA1 pathway. J. Biol. Chem. 285: 18473–18484, https://doi.org/10.1074/jbc.m110.118182.
Shao, B., Tang, C., Heinecke, J.W., and Oram, J.F. (2010b). Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export. J. Lipid Res. 51: 1849–1858, https://doi.org/10.1194/jlr.m004085.
Shao, B., Oda, M.N., Oram, J.F., and Heinecke, J.W. (2010c). Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem. Res. Toxicol. 23: 447–454, https://doi.org/10.1021/tx9003775.
Silvestre-Roig, C., de Winther, M.P., Weber, C., Daemen, M.J., Lutgens, E., and Soehnlein, O. (2014). Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies. Circ. Res. 114: 214–226, https://doi.org/10.1161/circresaha.114.302355.
Suc, I., Escargueil-Blanc, I., Troly, M., Salvayre, R., and Negre-Salvayre, A. (1997). HDL and apoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 17: 2158–2166, https://doi.org/10.1161/01.atv.17.10.2158.
Tauber, J.P., Cheng, J., and Gospodarowicz, D. (1980). Effect of high and low density lipoproteins on proliferation of cultured bovine vascular endothelial cells. J. Clin. Invest. 66: 696–708, https://doi.org/10.1172/jci109907.
Tauber, J.P., Cheng, J., Massoglia, S., and Gospodarowicz, D. (1981). High density lipoproteins and the growth of vascular endothelial cells in serum-free medium. Vitro 17: 519–530, https://doi.org/10.1007/bf02633513.
Torzewski, J., Bowyer, D.E., Waltenberger, J., and Fitzsimmons, C. (1997). Processes in atherogenesis: complement activation. Atherosclerosis 132: 131–138, https://doi.org/10.1016/s0021-9150(97)00100-7.
Tsai, J.C., Perrella, M.A., Yoshizumi, M., Hsieh, C.M., Haber, E., Schlegel, R., and Lee, M.E. (1994). Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc. Natl. Acad. Sci. U.S.A. 91: 6369–6373, https://doi.org/10.1073/pnas.91.14.6369.
Undurti, A., Huang, Y., Lupica, J.A., Smith, J.D., DiDonato, J.A., and Hazen, S.L. (2009). Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J. Biol. Chem. 284: 30825–30835, https://doi.org/10.1074/jbc.m109.047605.
Wang, G., Siow, Y.L., and O, K. (2000). Homocysteine stimulates nuclear factor kappaB activity and monocyte chemoattractant protein-1 expression in vascular smooth-muscle cells: a possible role for protein kinase C. Biochem. J. 352: 817–826, https://doi.org/10.1042/bj3520817.
Wilcken, D.E. and Wilcken, B. (1976). The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J. Clin. Invest. 57: 1079–1082, https://doi.org/10.1172/jci108350.
Yano, K., Ohkawa, R., Sato, M., Yoshimoto, A., Ichimura, N., Kameda, T., Kubota, T., and Tozuka, M. (2016). Cholesterol efflux capacity of apolipoprotein A-I varies with the extent of differentiation and foam cell formation of THP-1 cells. J. Lipids 2016: 9891316, https://doi.org/10.1155/2016/9891316.
Zhang, R., Brennan, M.L., Fu, X., Aviles, R.J., Pearce, G.L., Penn, M.S., Topol, E.J., Sprecher, D.L., and Hazen, S.L. (2001). Association between myeloperoxidase levels and risk of coronary artery disease. J. Am. Med. Assoc. 286: 2136–2142, https://doi.org/10.1001/jama.286.17.2136.
Zhang, Y., Zanotti, I., Reilly, M.P., Glick, J.M., Rothblat, G.H., and Rader, D.J. (2003). Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 108: 661–663, https://doi.org/10.1161/01.cir.0000086981.09834.e0.